[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594229":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":36,"locations":44,"responsibleParty":62,"collaborators":31,"id":64,"slug":65,"hasResults":66,"nctId":67,"briefTitle":68,"officialTitle":68,"acronym":31,"eligibilityCriteria":69,"healthyVolunteers":66,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":31,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":31,"overallStatus":47,"whyStopped":31,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"The First Affiliated Hospital of Zhengzhou University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1: cadonilizumab combined with neoadjuvant radiochemotherapy","EXPERIMENTAL","Subjects randomized in Arm 1 will be treated with cadonilizumab plus neoadjuvant radiochemotherapy before surgery.",[13],"Combination Product: cadonilizumab combined with neoadjuvant radiochemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Arm 2: neoadjuvant radiochemotherapy","PLACEBO_COMPARATOR","Subjects randomized in Arm 2 will be treated with neoadjuvant radiochemotherapy before surgery.",[19],"Combination Product: neoadjuvant radiochemotherapy",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"COMBINATION_PRODUCT","cadonilizumab combined with neoadjuvant radiochemotherapy","Subjects randomized to experimental arm will be treated with PD-1\u002FCTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy before surgery.",[9],[27],"neoadjuvant radiochemotherapy",{"type":22,"name":27,"description":29,"armGroupLabels":30,"otherNames":31},"Subjects in the arm 2, the control arm, will be treated with neoadjuvant radiochemotherapy.",[15],null,[33],{"name":34,"affiliation":5,"role":35},"Xiangbo Wan","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":31,"email":41},"Fuwei Wang","CONTACT","0086-037166278517","wanxbo@zzu.edu.cn",{"name":34,"role":39,"phone":43,"phoneExt":31,"email":41},"0086-037166271152",[45],{"facility":46,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"the First Affiliated Hospital of Zhengzhou University","RECRUITING","Zhengzhou","Henan","450000","China","CN",{"type":54,"coordinates":55},"Point",[56,57],113.64861,34.75778,{"lat":57,"lon":56},[60],{"name":61,"role":39,"phone":43,"phoneExt":31,"email":41},"Xiangbo Wan, Ph.D",{"type":35,"investigatorFullName":34,"investigatorTitle":63,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Vice-president of the First Affiliated Hospital of Zhengzhou University","100594229","phase-2-neoadjuvant-radiochemotherapy-combined-with-cadonilizumab-for-local-advanced-esophageal-squamous-cell-cancer-100594229",false,"NCT07016724","Neoadjuvant Radiochemotherapy Combined With Cadonilizumab for Local Advanced Esophageal Squamous Cell Cancer","Inclusion Criteria:\n\n* diagnosed with esophageal squamous cell cancer;\n* staged with cT1N+M0\u002FcT2-3N0-3M0;\n* experienced no cancer-related treatment;\n* ECOG 0-1;\n* Expected survival more than 6 months;\n* aimed at neoadjuvant therapy for surger;\n* have adquate organ function.\n\nExclusion Criteria:\n\n* diagnosed with other types of cancer during last five years;\n* have a tendency to bleed;\n* accepted any type of cancer-related therapy.","ALL","18 Years","75 Years",{"count":74,"type":75},208,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","Esophageal squamous cell cancer (ESCC) has a high incidence in China. Although the fast development of immune check point inhibitors (ICIs), the rate of pCR is limited with the mode of ICIs combined with neoadjuvant radiochemotherapy. The rate of pCR under ICIs combined with neoadjuvant radiochemotherapy was reported around 50%, which means more than half of those patients could not obtain pCR in reality. In order to explore a more effective mode of neoadjuvant therapy for ESCC, we designed this study to evaluate the effect of PD-1\u002FCTLA-4 bi-antibody, termed as cadonilizumab, combined with neoadjuvant radiochemotherapy in local advanced ESCC.",[81],"Esophageal Squamous Cell Carcinoma","2025-06-08",{"date":84,"type":85},"2025-06-12","ACTUAL",{"date":87,"type":85},"2024-08-15",{"date":89,"type":75},"2027-08-31",{"name":5,"class":6},1]